Drugmaker Eli Lilly Pauses Trial of COVID-19 Antibody Treatment

Drugmaker Eli Lilly Pauses Trial of COVID-19 Antibody Treatment

The trial's independent data safety monitoring board (DSMB) recommended the company pause enrollment, a Lilly spokesperson told CNBC in an email on Tuesday, adding, "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study". The treatment was halted due to a safety concern, leading the United States equity market to deepen losses.

The clinical trial is created to evaluate Lilly's neutralizing antibody as a treatment for COVID-19 in hospitalized patients in combination with the antiviral drug remdesivir.

MSCI's broadest index of Asia-Pacific shares outside of Japan.MIAPJ0000PUS fell 0.2 percent.

The Phase 3 trial of Johnson & Johnson's COVID-19 vaccine candidate has been paused as the company investigates what it says is a study participant's "unexplained illness".

Trials of that vaccine resumed in other regions after a brief halt.

The NIH designed the ACTIV-3 trial, unveiled in early August, to test experimental antibody treatments for COVID-19 in about 300 patients.

Both Lilly and Regeneron last week applied to the US Food and Drug Administration for emergency use authorizations for their treatments.

Our own immune systems produce antibodies, which are infection-fighting molecules, and vaccines teach our bodies to be prepared to make the right ones for particular pathogens.

It is administered intravenously by drip.

Lilly didn't disclose any details about the safety concern or how many people are affected.

Johnson & Johnson said it did not know if that person was given the vaccine or a placebo.

Thus far, more than 850 trial participants have been dosed, but the company said data from the trial is not yet available.

The Indianapolis-based drugmaker did not comment on the implications for the paused trial, called ACTIV-3, which is testing the treatment on Covid-19 patients who require hospitalization, or on its other ongoing trials.

Washington has given the multinational about $1.45 billion in funding under Operation Warp Speed.

Health and Human Services Secretary Alex Azar on coronavirus vaccine clinical trials. J&J used the same technology in its Ebola vaccine, which received marketing approval from the European Commission in July. The treatment is being developed with Canadian biotech AbCellera.

Related Articles